News & Updates
Showing Oncology articles
Showing
Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?
Research findings from Yonsei Cancer Center in South Korea, presented at European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025, suggest a correlation between butyrate-producing Faecalibacterium enrichment and clinical response to pembrolizumab with or without chemotherapy in treatment-naïve patients with metastatic non-small-cell lung cancer (mNSCLC).
Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?
23 Sep 2025
PORTEC-3: Adjuvant chemoradiotherapy improves 10-year OS in high-risk endometrial cancer
Adjuvant chemoradiotherapy (CRT) improves both 10-year overall survival (OS) and recurrence-free survival (RFS) in women with high-risk endometrial cancer vs pelvic radiotherapy alone, with the most clinically relevant benefit observed in p53 abnormal cancers, according to the 10-year analysis of the phase III PORTEC-3 trial.
PORTEC-3: Adjuvant chemoradiotherapy improves 10-year OS in high-risk endometrial cancer
15 Sep 2025
Enzalutamide plus radium-223 improves rPFS in mCRPC
First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.